New combo therapy targets tough lung cancer

NCT ID NCT06898957

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a combination of three drugs—tarlatamab, YL201, and durvalumab—in 29 adults with extensive stage small cell lung cancer that has progressed after prior treatment. The main goal is to check safety and side effects, while also measuring how well the tumors respond. It's a small, early study, so results will guide future research rather than offer a new treatment right away.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tarlatamab, YL201, and Durvalumab (anti-PD-L1)
What this could lead to: If successful, this could point toward a new combination treatment option for people with advanced small cell lung cancer.
What could go wrong: This is a very early, small phase 1b study focused on safety, not proof of effectiveness. The combination may cause serious side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER

Contacts and locations

Locations

Alexandra Hospital

Athens, 11528, Greece
Asan Medical Center

Seoul, 05505, South Korea
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Milan, 20162, Italy
CHU de Quebec Hopital de l Enfant Jesus

Québec, Quebec, G1J 1Z4, Canada
Centre Leon Berard

Lyon, 69373, France
City of Hope Orange County Lennar Foundation Cancer Center

Irvine, California, 92618, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Clinexpert Kft Bugat Pal Korhaz

Gyöngyös, 3200, Hungary
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
European Interbalkan Medical Center

Thessaloniki, 57001, Greece
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Fujian Cancer Hospital

Fuzhou, 350011, China
Gustave Roussy

Villejuif, 94805, France
Henry Dunant Hospital Center

Athens, 11526, Greece
Hospital Universitari Vall d Hebron

Barcelona, Catalonia, 08035, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Puerta de Hierro Majadahonda

Majadahonda, Madrid, 28222, Spain
Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08041, Spain
Iatriko Diavalkaniko Thessalonikis

Thessaloniki, 57001, Greece
Institut Bergonie

Bordeaux, 33000, France
Institut Universitaire du Cancer Toulouse Oncopole

Toulouse, 31059, France
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori

Meldola (FC), 47014, Italy
Istituto di Candiolo Fondazione del Piemonte per l Oncologia IRCCS

Candiolo to, 10060, Italy
Moffitt Cancer Center

Tampa, Florida, 33612, United States
Sanford Oncology Clinic and Pharmacy

Sioux Falls, South Dakota, 54104, United States
Sanford Roger Maris Cancer Center

Fargo, North Dakota, 58122, United States
Semmelweis Egyetem

Budapest, 1083, Hungary
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System

Seoul, 03722, South Korea
Shandong Cancer Hospital

Jinan, Shandong, 250117, China
Siteman Cancer Center

St Louis, Missouri, 63110, United States
Swedish Medical Center

Seattle, Washington, 98104, United States
Universitaetsklinikum Essen

Essen, 45147, Germany
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
West China Hospital of Sichuan University

Chengdu, Sichuan, 611135, China
Yale New Haven Hospital

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.